Intra-Cellular Therapies Inc. (ITCI) insider have most recently took part in a trading activity. On Nov 22, 2017 Alafi Christopher D, Director, 10% Owner bought 10,000 shares having total worth of $155,500 at the price of $15.55 per share, following the transaction a total of 5,201,489 shares owned by Alafi Christopher D. Before this latest buy, Alafi Christopher D purchased ITCI at 1 other times during the past twelve months, for a total investment of $10.58M at an average of $16.27 per share.
The stock has experienced a total of 1 insider trades in the past three months. These trades include 1 sell activities .Furthermore, over the past 12 months , the stock was traded 9 times by insiders. In 6 of these trades, the insider was a seller while an employee of the company was the buyer in 3 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Intra-Cellular Therapies Inc. (ITCI) traded up 1.4% on Nov 24, 2017, hitting $15.91. 180,100 shares of the company’s stock traded hands. Intra-Cellular Therapies Inc. has a 52 week low of $9.26 and a 52 week high of $44.48. The company’s market cap is $1,800 million.
Intra-Cellular Therapies Inc. (ITCI) last announced its earnings results on Nov 8, 2017. The company reported -0.53 earnings per share (EPS) for the quarter, higher than the consensus estimate of -0.62 by $0.09. The company had revenue of $0 million for the quarter, compared to the consensus estimate of $0 million. During the same quarter in the previous year, the company posted -0.70 earnings per share. The company’s revenue for the quarter was up 605% on a year-over-year basis.
|earnings per share||-0.53||-0.41||-0.62||-0.64||-0.70||-0.71|
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018